Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

trametinib 3dabrafenib 3talimogene laherparepvec 2pembrolizumab 2Nivolumab 2Ipilimumab 2ulixertinib 1tebentafusp 1pegilodecakin 1omaveloxolone 1methyl 5-aminolevulinate 1lifileucel 1efineptakin alfa 1cemiplimab 1balstilimab 1avelumab 1aldesleukin 1Rose Bengal 1Melphalan 1HhAntag691 1Cyclophosphamide 1Brentuximab Vedotin 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × pegilodecakin × Dermatologic × Clear all
NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡